Shorted
Mesoblast logo
MSB
Pharmaceuticals, Biotechnology & Life Sciences

Mesoblast

Short interest
7.73%
+0.40 pp 30d
as of 12 Oct 2026
Reported shorts
100.4M
Shares on issue
1.299B

Mesoblast (MSB) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Negative
8h ago

Why Did Mesoblast (ASX:MSB) Fall Despite Strong Ryoncil Growth?

Highlights Mesoblast's first-quarter Ryoncil net revenue rose strongly on a year earlier. Net operating cash spend improved sharply, leaving a solid cash balance. Revenue was below the level reported in the June quarter, which the company linked to seasonal summer patterns. Mesoblast (ASX:MSB), the Melbourne-based developer of cell therapies, reported strong year-on-year growth in sales of its first commercial product, Ryoncil. But the shares fell sharply on Friday, suggesting investors focus...

Continue reading
Kalkine
Negative
2d ago

Why Is Mesoblast (ASX:MSB) Sliding Despite Ryoncil Sales Growth?

Highlights Mesoblast shares fell sharply on Friday morning, making it the worst performer in the benchmark ASX index early in the session. The cell therapy company's revenue jumped last financial year, driven by sales of its Ryoncil therapy in the US. The company remains loss-making, and its shares are well down over the past year. Mesoblast (ASX:MSB), the Melbourne-based developer of cell-based medicines, was the biggest decliner in the benchmark ASX index on Friday morning, even as the broa...

Continue reading
Kalkine
Neutral
2d ago

What is ahead for Mesoblast (ASX:MSB) as its AGM approaches?

Highlights Mesoblast has released its annual report covering its debut full year as a commercial company The company's annual general meeting is set for November in Melbourne Several pipeline programs remain in development with regulatory steps ahead Mesoblast Limited (ASX:MSB) has spent years trying to prove that cell therapy can work as a commercial business, and its latest annual report offers the clearest picture yet of how that transition is unfolding. The Melbourne-based developer of al...

Continue reading
Kalkine
Positive
4d ago

Is Mesoblast (ASX:MSB) Proving Its Ryoncil Launch?

Highlights initial full year of sales for its cell therapy lifted revenue sharply on the prior year A new multi-year credit facility adds funding without issuing shares Late stage trials in back pain and adult transplant complications remain the next tests Mesoblast (ASX:MSB), the regenerative medicine company listed on both the Australian exchange and Nasdaq, has filed its annual report showing that Ryoncil, its cell therapy for children with steroid-refractory acute graft-versus-host diseas...

Continue reading
Kalkine
Neutral
9 Oct

Is Mesoblast (ASX:MSB) Ready to Turn Ryoncil Into a Franchise?

Highlights The cell therapy company has moved from a tiny revenue base to a sizeable one in a year A plan to extend its lead drug to adult patients could triple the addressable market Losses are narrowing but the pipeline still needs funding Mesoblast (ASX:MSB), the Melbourne-based cell therapy company dual-listed in New York, is trying to turn its first approved product, Ryoncil, into a platform business, with plans to widen its use to adult patients after a year of rapid revenue growth. Inv...

Continue reading
Kalkine
Neutral
6 Oct

Will Mesoblast's Back Pain Trial Define Its Year (ASX:MSB)?

Highlights Mesoblast has finished treating patients in its pivotal back pain trial. The trial enrolled more patients than first planned after strong investigator demand. Top-line results are expected around the middle of next year. Mesoblast (ASX:MSB) remains on the healthcare radar as the market counts down to results from its pivotal chronic low back pain trial, having completed patient treatment in mid-August in what the cell therapy company calls a major milestone for what it hopes will b...

Continue reading
Kalkine
Neutral
28 Sept

Has Mesoblast (ASX:MSB) cleared a key FDA manufacturing hurdle?

Highlights US regulators have signed off on a new quality test used to release commercial batches of the company's approved cell therapy. The approval supports manufacturing changes and new production sites as the stem cell developer scales up supply. Label expansion into adults and a late-stage back pain readout next year remain the bigger value drivers. Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration to use a new potency assay for releasing every new comme...

Continue reading
Kalkine
Positive
24 Aug

ASX:MSB Mesoblast: Why Is Its Growth Story Back in Focus?

Highlights Mesoblast is drawing attention as its commercial-stage cell-therapy strategy becomes increasingly important to the company narrative. The biotechnology groups progress depends on commercial execution, regulatory pathways and the ability to expand adoption of its specialised therapies. Market attention is shifting from development milestones towards how effectively the company can translate its platform into a durable operating business. Australian biotechnology names can move quick...

Continue reading
Kalkine
Positive
23 Aug

Could Mesoblast (ASX:MSB), Telix (ASX:TLX) and Lindian (ASX:LIN) Stay in Growth Focus?

Highlights Mesoblast (ASX:MSB) remains in focus as its regenerative medicine pipeline advances through important clinical and commercial stages. Telix Pharmaceuticals (ASX:TLX) continues expanding its precision oncology platform across imaging and therapeutic applications. Lindian Resources (ASX:LIN) is progressing its rare earth development strategy as attention remains on diversified critical mineral supply chains. Australian growth shares continue attracting attention as investors look beyo...

Continue reading
Kalkine
Positive
23 Aug

Could Mesoblast (ASX:MSB), Westgold (ASX:WGX) and Lynas (ASX:LYC) Stay in Growth Focus?

Highlights Mesoblast (ASX:MSB) remains closely watched as its late-stage regenerative medicine programs progress through important clinical development stages. Westgold Resources (ASX:WGX) is drawing attention as operational expansion, mine development and integration shape its gold production profile. Lynas Rare Earths (ASX:LYC) remains exposed to growing strategic interest in non-Chinese rare earth supply chains and advanced materials. Australian growth shares remain an important area of mar...

Continue reading
Kalkine
Positive
23 Aug

Mesoblast (ASX:MSB) Leads 3 Australian Growth Stocks in Focus

Highlights Mesoblast, Telix Pharmaceuticals and Lindian Resources have emerged among closely watched Australian growth companies with notable insider ownership. Healthcare innovation and rare earth development continue to shape attention across the Australian share market. Each company faces unique operational milestones alongside sector-specific challenges that could influence future business progress. Australia's equity market continues to spotlight companies pursuing ambitious expansi...

Continue reading
Kalkine
Positive
21 Aug

Mesoblast (ASX:MSB) Leads 3 Australian Growth Stocks to Watch

Highlights Mesoblast, Predictive Discovery and Telix Pharmaceuticals are gaining attention for their growth-focused business strategies. Healthcare and gold sectors continue to attract market interest despite global economic uncertainty. Strong project pipelines and commercial progress remain central themes across these Australian-listed companies. Australia's share market continues to navigate a challenging global backdrop as central banks weigh future interest rate decisions and inflat...

Continue reading
Kalkine
Neutral
20 Aug

Are These Penny Stocks Worth Watching? MSB, CLOV and HYLN

Highlights Mesoblast (ASX:MSB) is advancing a focused cell therapy platform supported by regulatory progress and clinical development programs. Clover Health Investments (NASDAQ:CLOV) combines Medicare Advantage insurance with data-driven healthcare technology. Hyliion Holdings (NYSE:HYLN) is developing flexible distributed power technology through its KARNO Power Module. Balance sheet resilience remains particularly important for smaller companies that depend on external capital to support expa...

Continue reading
Kalkine
Neutral
11 Aug

Can Mesoblast (ASX:MSB) Prove Commercial Launch Manufacturing?

Highlights Mesoblast remains in focus as investors assess commercial launch and manufacturing readiness through research discipline, a key indicator of whether current momentum can translate into durable operating progress. August reporting season is sharpening attention on procedure demand and reimbursement quality, helping investors distinguish headline activity from the underlying quality of the business outlook. A key risk is that currency and labour costs can cloud underlying progress, whi...

Continue reading
Kalkine
Neutral
5 Aug

State Street Corporation Acquires 5.01% Stake in Mesoblast Limited, Becoming a Substantial Shareholder

Mesoblast Limited (ASX:MSB) has been notified of an initial substantial holding by State Street Corporation and its designated subsidiaries, revealing that the group attained substantial shareholder status on 3 August 2026, holding 5.01% voting power through 65,124,909 ordinary shares. Key Points State Street Corporation and its named subsidiaries became substantial holders in Mesoblast Limited as of 3 August 2026. The group holds a relevant interest in 65,124,909 ordinary shares, equating to...

Continue reading
Kalkine
Neutral
3 Aug

State Street Corporation and Subsidiaries End Substantial Holding in Mesoblast Limited (ASX:MSB)

Mesoblast Limited (ASX:MSB) announced that State Street Corporation along with its subsidiaries officially ceased to be substantial holders in the company as of 30 July 2026, based on a Form 605 Notice of Ceasing to be a Substantial Holder filed with the exchange on 3 August 2026. Key Highlights On 30 July 2026, State Street Corporation and its specified subsidiaries stopped being substantial holders in Mesoblast Limited. The prior substantial holding notice was submitted on 31 July 2026 and ...

Continue reading
Kalkine
Neutral
28 July

Could Mesoblast (ASX:MSB), Lynas (ASX:LYC) and WiseTech (ASX:WTC) Be Undervalued on Cash Flow?

Highlights Mesoblast, Lynas Rare Earths and WiseTech Global are drawing attention through cash-flow-based valuation assessments. Each company operates in a structural growth sector spanning biotechnology, critical minerals and logistics software. Commercial execution, funding discipline and long-term cash generation remain key themes for investors. Global markets continue navigating changing inflation expectations, evolving interest-rate outlooks and ongoing geopolitical uncertainty. In this e...

Continue reading
Kalkine
Neutral
27 July

Why Is Mesoblast (ASX:MSB) Back on the Radar?

Highlights Small-cap biotech names drew attention as clinical and regulatory milestones offered stock-specific catalysts. Cell-therapy developer Mesoblast anchored the theme as it advanced its commercial and pipeline ambitions. Imugene and Neuren Pharmaceuticals rounded out a small-cap biotech cohort tied to cancer and neurological therapies. Mesoblast (ASX:MSB) drew attention among the ASX small-cap biotech names today as the cell-therapy developer advanced its commercial and clinical ambiti...

Continue reading